Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients. 

The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

In Science this week: circulating tumor DNA to identify colorectal cancer and predict survival, and more.

A Sun-Yat Sen University Cancer Center-led team found circulating tumor DNA methylation patterns could detect colorectal cancer among asymptomatic individuals.

The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.

Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.

Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.

The researchers profiled 44 cancer-related genes in 191 individuals with familial breast cancer, colorectal cancer, or other forms of early-onset cancer.

The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.

Pages

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.